Oramed Pharmaceuticals Technology Patented with WIPO

JERUSALEM, Sept. 13  /PRNewswire/ -- Oramed Pharmaceuticals is excited to announce the patent application of a PCT (Patent Cooperation Treaty) for the Methods and Compositions for Oral Administration of Proteins has been approved and filed with WIPO (World Intellectual Property Organization).  The application was filed on August 31, 2006, at the Israel Patent Office (IPO), acting as Receiving Office for the WIPO.  Priority was claimed from 60/713,716, all countries were designated and the United States Patent and Trademark Office (USPTO) was designated as Search and Examination Authority.

This is expected to ensure global patent protection for Oramed's proprietary technology to deliver insulin orally.

About WIPO

The World Intellectual Property Organization (WIPO) is a specialized agency of the United Nations. It is dedicated to developing a balanced and accessible international intellectual property (IP) system, which rewards creativity, stimulates innovation and contributes to economic development while safeguarding the public interest.

  The five strategic goals of WIPO include:

  *  To promote an IP culture;
  *  To integrate IP into national development policies and programs;
  *  To develop international IP laws and standards;
  *  To deliver quality services in global IP protection systems; and
  *  To increase the efficiency of WIPO's management and support processes.

  About Oramed Pharmaceuticals:


Oramed Pharmaceuticals is an Israeli based company focused on the development of oral delivery solutions based on proprietary technology. Diabetes is one of the most rapidly growing diseases in the world and is one that requires constant and often unpleasant monitoring and drug therapy regimen. Oramed is currently developing an orally ingestible soft gel insulin capsule for the treatment of diabetes. The Company is also pursuing the development of oral delivery solutions for other drugs and vaccines.

  For more information please visit our website at http://www.oramedpharma.com/

  Investor Relations Contact:
  Oramed Pharmaceuticals, Inc.
  Vinisha Agnihotri
  [phone]
  
  http://www.oramedpharma.com/

  Legal Notice Regarding Forward Looking Statements


This news release contains statements, which may constitute "forward- looking statements". Those statements include statements regarding the intent, belief or current expectations of Oramed Pharmaceutical Inc., and members of our management as well as the assumptions on which such statements are based. Forward-looking statements in this release include: that we are currently developing an orally ingestible soft gel insulin capsule for the treatment of diabetes and for other diseases; that our approved patent will protect our proprietary technology; and the potential of our future products relating to oral insulin. Factors which may significantly change or prevent our forward looking statements from fruition include that we may be unsuccessful in developing any products; we may be unable to raise funds and resources to pursue research and development, we may be unable to successfully defend our patents from infringement by third parties, there is a risk that our patent may be subsequently shown to be invalid or infringe the patents of others, our products may never gain FDA or other regulatory body approval for human consumption and we may be unable to successfully commercialise our future products. Readers should refer to our most recent 10-KSB filed on Edgar and the 8-K announcing our acquisition of the Oramed technology filed March 8, 2006. 

DATASOURCE: Oramed Pharmaceuticals



CONTACT:  Vinisha Agnihotri, Investor Relations, of Oramed

Pharmaceuticals, Inc., [phone],  



Web site:  http://www.oramedpharma.com/ 

Copyright